Brand Name Pharmaceutical Manufacturing in the US - Market Research Report (2014-2029)
New York, United States
Last Updated: July 2024
NAICS 32541aRevenue
$261.2bn
Past 5-Year Growth
Profit
$XX.Xbn
Employees
283k
Businesses
2,446
Wages
$XX.Xbn
Brand Name Pharmaceutical Manufacturing in the US industry analysis
Brand name pharmaceutical manufacturers in the US are some of the most lucrative in the world. Consumers in the US use and spend more on prescription drugs than any other country, making manufacturers central to meeting this demand and supporting public health. This role was evident during the COVID-19 pandemic, as brand name pharma producers researched, produced and distributed vital vaccines in record time. Aside from vaccine development, domestic manufacturers can attribute rising spending on brand name drugs to several factors, including an aging population, expanding health coverage, new drug approvals and medical advances in expensive specialty areas like rare diseases and oncology. Still, mounting scrutiny facing brand name pharma makers focuses on pricing policies and patent protections, suggesting that the industry’s strong performance indicates monopolistic practices and price hikes rather than rising prescription drug use. In all, revenue has been growing at a CAGR of 3.7% over the past five years to an estimated $261.2 billion, including expected growth of 1.4% in 2024.
Trends and Insights
- A number of leading pharma producers are confronting patent expirations. Losing market exclusivity can result in billions in losses, prompting manufacturers to strengthen R&D investments and look toward acquisitions to bolster pipelines.
- Funding and research support the development of oncology drugs. Pharma leaders and innovative start-ups introduce new cancer treatments that healthcare providers and patients seek.
- Mid-Atlantic states are global pharmaceutical centers. New Jersey is a hub for multinational pharmaceutical manufacturers, providing new and existing companies with a healthy life sciences ecosystem to operate and expand.
- Biosimilars are one of the largest threats to brand name pharmaceutical producers. Patents protect brand name manufacturers for a set time, but the entry of biosimilars when they expire exposes manufacturers to steep competition.
Industry Overview
Market size and recent performance (2014-2029)
Industry revenue has grown at a CAGR of 3.7 % over the past five years, to reach an estimated $261.2bn in 2024.
Trends and Insights
Spending on brand name prescription drugs balloons
- Brand name pharmaceutical manufacturers in the US position as some of the world's largest healthcare companies has only been cemented in recent years. Rising spending on brand name drugs can be attributed to a combination of several factors, including an aging population, growing rates of chronic illnesses, expanding health coverage, new drug approvals and medical advances in expensive specialty areas.
- Additional trends and insights available with purchase
Source: IBISWorld
Industry outlook (2024-2029)
Market size is projected to grow over the next five years.
Trends and Insights
Patent expirations will represent the major threat over the next five years
- In the next five years, key patents are expected to expire for such blockbuster brands as Revlimid by Bristol-Myers Squibb (2025-2026), Eylea by Regeneron Pharmaceuticals and Bayer (2025-2026), Stelara by Johnson & Johnson (2025-2026), Eliquis by Bristol-Myers Squibb and Pfizer (2027-2029) and Keytruda by Merck & Co. (2028).
Biggest companies in the Brand Name Pharmaceutical Manufacturing in the US
| Company | Market Share (%)
2024 | Revenue ($m)
2024 | Profit ($m)
2024 | Profit Margin (%)
2024 |
|---|---|---|---|---|
Merck & Co | 34,472.9 | 4,253.7 | 12.3 | |
Pfizer Inc. | 33,641.7 | 1,224.3 | 3.6 | |
Abbvie inc. | 28,703.2 | 3,359.0 | 11.7 |
To view the market share and analysis for all 12 top companies in this industry, view purchase options.
Products & Services Segmentation
Source: IBISWorld
Industry revenue is measured across several distinct product and services lines, including Diabetes prescriptions, Oncology prescriptions and Autoimmune prescriptions. Diabetes prescriptions is the largest segment of the Brand Name Pharmaceutical Manufacturing in the US.
Trends and Insights
Demand for type 1 diabetes prescriptions has grown substantially
- This segment includes medications for both type 1 and type 2 diabetes. These drugs include but are not limited to insulin, alpha-glucosidase inhibitors, biguanides and dopamine agonists.
- More insights available in the full report
Widen you competitive advantage with related industries
Competitors
- Generic Pharmaceutical Manufacturing in the US
- Biotechnology in the US
Complementors
- Cosmetic & Beauty Products Manufacturing in the US
- Drug, Cosmetic & Toiletry Wholesaling in the US
- Pharmacies & Drug Stores in the US
- Scientific Research & Development in the US
International industries
- Global Pharmaceuticals & Medicine Manufacturing
- Brand-Name Pharmaceutical Manufacturing in Canada
- Pharmaceutical Product Manufacturing in Australia
- Pharmaceutical Preparations Manufacturing in the UK
- Pharmaceutical Preparations Manufacturing in Ireland
Table of Contents
About this industry
Industry definition
Brand name pharmaceutical manufacturers develop, produce and market pharmaceutical drugs under their proprietary brand names. These manufacturers often hold patents or other intellectual property rights to their drugs, granting them sole exclusivity to produce, distribute and sell their drug for the entire life of the patent.
What's included in this industry?
Pharmaceutical research and developmentManufacturing active ingredients used in pharmaceuticalsManufacturing chemical pharmaceutical preparationsManufacturing biological pharmaceutical productsCompanies
Merck & CoPfizer Inc.Abbvie inc.Purchase this report to view all 12 major companies in this industry.
Related Terms
BIOLOGICBIOSIMILARORPHAN DRUGPATENT CLIFFOUTSOURCEOVER-THE-COUNTER BLOCKBUSTER DRUGIndustry Code
NAICS 325411 - Brand Name Pharmaceutical Manufacturing in the US
Performance
Get an indication of the industry's health through historical, current and forward-looking trends in the performance indicators that make or break businesses.
Analyst insights
A number of leading pharma producers are confronting patent expirations. Losing market exclusivity can result in billions in losses, prompting manufacturers to strengthen R&D...
In this chapter (4)
- Current Performance
- Outlook
- Volatility
- Life Cycle
Key metrics
- Annual Revenue, Recent Growth, Forecast, Revenue Volatility
- Number of Employees, Recent Growth, Forecast, Employees per Business, Revenue per Employee
- Number of Businesses, Recent Growth, Forecast, Employees per Business, Revenue per Business
- Total Profit, Profit Margin, Profit per Business
Charts
- Revenue, including historical (2014-2023) and forecast (2024-2029)
- Employees, including historical (2014-2023) and forecast (2024-2029)
- Businesses, including historical (2014-2023) and forecast (2024-2029)
- Profit, including historical (2014-2024)
- Industry Volatility vs. Revenue Growth
- Industry Life Cycle
Detailed analysis
- Trends in supply, demand and current events that are driving current industry performance
- Expected trends, economic factors and ongoing events that drive the industry's outlook
- Key success factors for businesses to overcome volatility
- How contribution to GDP, industry saturation, innovation, consolidation, and technology and systems influence the industry's life cycle phase.
Products and Markets
Learn about an industry's products and services, markets and trends in international trade.
Analyst insight
Funding and research support the development of oncology drugs. Pharma leaders and innovative start-ups introduce new cancer treatments that healthcare providers and patients...
In this chapter
- Products & Services
- Major Markets
- International Trade
Key metrics
- Largest market segment and value in 2024
- Product innovation level
- Total imports, level and trend
- Total exports, level and trend
- Trade Balance
Charts
- Products & services segmentation in 2024
- Major market segmentation in 2024
- International trade, including imports by country and exports by country
Detailed analysis
- Trends impacting the recent performance of the industry's various segments
- Innovations in the industry's product or service offering, specialization or delivery method
- Key factors that successful businesses consider in their offerings
- Buying segments and key trends influencing demand for industry products and services
- Recent trends in import and export volumes, country of origin or destination, and expected future trends
Geographic Breakdown
Discover where business activity is most concentrated in an industry and the factors driving these trends to find opportunities and conduct regional benchmarking.
Analyst insights
Mid-Atlantic states are global pharmaceutical centers. New Jersey is a hub for multinational pharmaceutical manufacturers, providing new and existing companies with a healthy...
In this chapter (1)
- Business Locations
Charts
- Share of revenue, establishment, wages and employment in each state
- Share of population compared to establishments in each region in 2024
Tables
- Number and share of establishments in each state in 2024
- Number and share of revenue each state accounts for in 2024
- Number and share of wages each state accounts for in 2024
- Number and share of employees in each state in 2024
Detailed analysis
- Geographic spread of the industry across North America, and trends associated with changes in the business landscape
- Key success factors for businesses to use location to their advantage
Competitive Forces
Get data and insights on what's driving competition in an industry and the challenges industry operators and new entrants may face, with analysis built around Porter's Five Forces framework.
Analyst insights
Biosimilars are one of the largest threats to brand name pharmaceutical producers. Patents protect brand name manufacturers for a set time, but the entry of biosimilars when ...
In this chapter (4)
- Concentration
- Barriers to Entry
- Substitutes
- Buyer & Supplier Analysis
Key metrics
- Industry concentration level
- Industry competition level and trend
- Barriers to entry level and trend
- Substitutes level and trend
- Buyer power level and trend
- Supplier power level and trend
Charts
- Market share concentration among the top 4 suppliers from 2019-2024
- Supply chain including upstream supplying industries and downstream buying industries, flow chart
Detailed analysis
- Factors impacting the industry’s level of concentration, such as business distribution, new entrants, or merger and acquisition activity.
- Key success factors for businesses to manage the competitive environment of the industry.
- Challenges that potential industry entrants face such as legal, start-up costs, differentiation, labor/capital intensity and capital expenses.
- Key success factors for potential entrants to overcome barriers to entry.
- Competitive threats from potential substitutes for the industry’s own products and services.
- Key success factors for how successful businesses can compete with substitutes.
- Advantages that buyers have to keep favorable purchasing conditions.
- Advantages that suppliers have to maintain favorable selling conditions.
- Key success factors for how businesses can navigate buyer and supplier power.
Companies
Learn about the performance of the top companies in the industry.
Analyst insights
Leading pharmaceutical producers spend billions annually on research and development. Massive drug sales and profits allow these manufacturers to invest in drug development a...
In this chapter
- Market Share Concentration
- Companies
- Company Spotlights
Charts
- Industry market share by company in 2020 through 2024
- Major companies in the industry, including market share, revenue, profit and profit margin in 2024
- Overview of Merck & Co's performance by revenue, market share and profit margin from 2018 through 2024
- Overview of Pfizer Inc.'s performance by revenue, market share and profit margin from 2018 through 2024
- Overview of Abbvie inc.'s performance by revenue, market share and profit margin from 2018 through 2024
- Overview of revenue, market share and profit margin trend for 9 additional companies
Detailed analysis
- Description and key data for Merck & Co, and factors influencing its performance in the industry
- Description and key data for Pfizer Inc., and factors influencing its performance in the industry
- Description and key data for Abbvie inc., and factors influencing its performance in the industry
- Description, key data and performance trends for 9 additional companies
External Environment
Understand the demographic, economic and regulatory factors that shape how businesses in an industry perform.
Analyst insights
Pharmaceuticals’ direct impact on public health exposes the industry to many regulations. Brand name pharma producers must navigate a complex environment overseeing R&D, clin...
In this chapter
- External Drivers
- Regulation & Policy
- Assistance
Key metrics
- Regulation & policy level and trend
- Assistance level and trend
Charts
- Regulation & Policy historical data and forecast (2014-2029)
- Assistance historical data and forecast (2014-2029)
Detailed analysis
- Demographic and macroeconomic factors influencing the industry, including Regulation & Policy and Assistance
- Major types of regulations, regulatory bodies, industry standards or specific regulations impacting requirements for industry operators
- Key governmental and non-governmental groups or policies that may provide some relief for industry operators.
Financial Benchmarks
View average costs for industry operators and compare financial data against an industry's financial benchmarks over time.
Analyst insights
Profit varies widely between brand name pharmaceutical producers. A host of competing factors like patent cliffs, new market approvals or external events all have a role in i...
In this chapter
- Cost Structure
- Financial Ratios
- Key Ratios
Key metrics
- Profit margin, and how it compares to the sector-wide margin
- Average wages, and how it compares to the sector-wide average wage
- Largest cost component as a percentage of revenue
- Industry average ratios for days' receivables, industry coverage and debt-to-net-worth ratio
Charts
- Average industry operating costs as a share of revenue, including purchases, wages, depreciation, utilities, rent, other costs and profit in 2024
- Average sector operating costs as a share of revenue, including purchases, wages, depreciation, utilities, rent, other costs and profit in 2024
- Investment vs. share of economy
Data tables
- Industry Multiples (2017-2022)
- Industry Tax Structure (2017-2022)
- Income Statement (2017-2022)
- Balance Sheet (2017-2022)
- Liquidity Ratios (2017-2022)
- Coverage Ratios (2017-2022)
- Leverage Ratios (2017-2022)
- Operating Ratios (2017-2022)
- Cash Flow & Debt Service Ratios (2014-2029)
- Revenue per Employee (2014-2029)
- Revenue per Enterprise (2014-2029)
- Employees per Establishment (2014-2029)
- Employees per Enterprise (2014-2029)
- Average Wage (2014-2029)
- Wages/Revenue (2014-2029)
- Establishments per Enterprise (2014-2029)
- IVA/Revenue (2014-2029)
- Imports/Demand (2014-2029)
- Exports/Revenue (2014-2029)
Detailed analysis
- Trends in the cost component for industry operators and their impact on industry costs and profitability
Key Statistics
Industry Data
Data Tables
Including values and annual change:
- Revenue (2014-2029)
- IVA (2014-2029)
- Establishments (2014-2029)
- Enterprises (2014-2029)
- Employment (2014-2029)
- Exports (2014-2029)
- Imports (2014-2029)
- Wages (2014-2029)
Methodology
How are IBISWorld reports created?
IBISWorld has been a leading provider of trusted industry research for over 50 years to the most successful companies worldwide. With offices in Australia, the United States, the United Kingdom, Germany and China, we are proud to have local teams of analysts that conduct research, data analysis and forecasting to produce data-driven industry reports.
Our analysts start with official, verified and publicly available sources of data to build the most accurate picture of each industry. Analysts then leverage their expertise and knowledge of the local markets to synthesize trends into digestible content for IBISWorld readers. Finally, each report is reviewed by one of IBISWorld’s editors, who provide quality assurance to ensure accuracy and readability.
IBISWorld relies on human-verified data and human-written analysis to compile each standard industry report. We do not use generative AI tools to write insights, although members can choose to leverage AI-based tools within the platform to generate additional analysis formats.
What data sources do IBISWorld analysts use?
Each industry report incorporates data and research from government databases, industry-specific sources, industry contacts, and our own proprietary database of statistics and analysis to provide balanced, independent and accurate insights.
Key data sources in the US include:
- US Census Bureau
- US Bureau of Labor Statistics
- US International Trade Commission
Analysts also use industry specific sources to complement catch-all sources, although their perspective may focus on a particular organization or representative body, rather than a clear overview of all industry operations. However, when balanced against other perspectives, industry-specific sources provide insights into industry trends.
These sources include:
- Industry and trade associations
- Industry federations or regulators
- Major industry players annual or quarterly filings
Finally, IBISWorld’s global data scientists maintain a proprietary database of macroeconomic and demand drivers, which our analysts use to help inform industry data and trends. They also maintain a database of statistics and analysis on thousands of industries, which has been built over our more than 50-year history and offers comprehensive insights into long-term trends.
How does IBISWorld forecast its data?
IBISWorld’s analysts and data scientists use the sources above to create forecasts for our proprietary datasets and industry statistics. Depending on the dataset, they may use regression analysis, multivariate analysis, time-series analysis or exponential smoothing techniques to project future data for the industry or driver. Additionally, analysts will leverage their local knowledge of industry operating and regulatory conditions to impart their best judgment on the forecast model.
IBISWorld prides itself on being a trusted, independent source of data, with over 50 years of experience building and maintaining rich datasets and forecasting tools. We are proud to be the keystone source of industry information for thousands of companies across the world.
Learn more about our methodology and data sourcing on the Help Center.
Frequently Asked Questions
Unlock comprehensive answers and precise data upon purchase. View purchase options.
What is the market size of the Brand Name Pharmaceutical Manufacturing in the US industry in United States in 2024?
The market size of the Brand Name Pharmaceutical Manufacturing in the US industry in United States is $261.2bn in 2024.
How many businesses are there in the Brand Name Pharmaceutical Manufacturing in the US industry in 2024?
There are 2,446 businesses in the Brand Name Pharmaceutical Manufacturing in the US industry in United States, which has grown at a CAGR of 7.1 % between 2019 and 2024.
Has the Brand Name Pharmaceutical Manufacturing in the US industry in United States grown or declined over the past 5 years?
The market size of the Brand Name Pharmaceutical Manufacturing in the US industry in United States has been growing at a CAGR of 3.7 % between 2019 and 2024.
What is the forecast growth of the Brand Name Pharmaceutical Manufacturing in the US industry in United States over the next 5 years?
Over the next five years, the Brand Name Pharmaceutical Manufacturing in the US industry in United States is expected to grow.
What are the biggest companies in the Brand Name Pharmaceutical Manufacturing in the US market in United States?
The biggest companies operating in the Brand Name Pharmaceutical Manufacturing market in United States are Merck & Co, Pfizer Inc. and Abbvie inc.
What does the Brand Name Pharmaceutical Manufacturing in the US in United States include?
Pharmaceutical research and development and Manufacturing active ingredients used in pharmaceuticals are part of the Brand Name Pharmaceutical Manufacturing in the US industry.
Which companies have the highest market share in the Brand Name Pharmaceutical Manufacturing in the US in United States?
The company holding the most market share in United States is Merck & Co.
How competitive is the Brand Name Pharmaceutical Manufacturing in the US industry in United States?
The level of competition is high and increasing in the Brand Name Pharmaceutical Manufacturing in the US industry in United States.
